The notices it replaced
- Reissues: RFA-NS-22-071 Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
Replaced by RFA-NS-24-029.
Who won it before
4 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $50,667,952 in first-year total cost, median $11,197,636.
Most frequent study sections
- Special Emphasis Panel[ZNS1 SRB-E (05)]4
Most frequent institutions
- MASSACHUSETTS GENERAL HOSPITAL3
- COLUMBIA UNIVERSITY HEALTH SCIENCES1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2023 | Intermediate-Size Expanded Access Trial of Autologous Hybrid TREG/Th2 Cell Therapy (RAPA-501) of Amyotrophic Lateral Sclerosis1U01NS136020-01 | BABU, SUMABERRY, JAMES DALEPAGANONI, SABRINA | MASSACHUSETTS GENERAL HOSPITAL, MA | $11,203,040 | ZNS1 |
| 2023 | Intermediate-sized Expanded Access Protocol for CNM-Au8 in Amyotrophic Lateral Sclerosis (ALS).1U01NS136023-01 | ANDERSON, ERICANDREWS, JINSYGREENBERG, BENJAMIN M | COLUMBIA UNIVERSITY HEALTH SCIENCES, NY | $11,192,232 | ZNS1 |
| 2023 | An Intermediate-Size Expanded Access Protocol for Amyotrophic Lateral Sclerosis with Pridopidine1U01NS136021-01 | BABU, SUMABERRY, JAMES DALEPAGANONI, SABRINA | MASSACHUSETTS GENERAL HOSPITAL, MA | $10,136,176 | ZNS1 |
| 2022 | An Expanded Access Protocol of Intravenous Trehalose Injection 90 mg/mL Treatment of Patients with Amyotrophic Lateral Sclerosis1UF1NS131791-01 · under RFA-NS-22-071 | BABU, SUMABERRY, JAMES DALEPAGANONI, SABRINA | MASSACHUSETTS GENERAL HOSPITAL, MA | $18,136,504 | ZNS1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-12-0.1.3. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.